Biogen (BIIB) stock soars following positive Alzheimer’s drug trial. Salim Syed discusses this as Mizuho upgraded BIIB to buy from neutral and raised its price target to $270 from $207. He talks about how this new drug is likely to receive regulatory approval.He then goes over expectations for biopharmaceutical stocks. Tune in to find out more about the stock market today.
The Watch List
28 Sep 2022
SHARE
Trading 360
10 Jul 2023
Next Gen Investing
05 Jul 2023
Morning Trade Live
08 Aug 2023
Market On Close
07 Jul 2023
Trading 360
29 Jun 2023
Morning Trade Live
10 Jul 2023